2024
Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial
Nouhravesh N, Clare R, Wojdyla D, Anstrom K, Velazquez E, Greene S, Pitt B, Mentz R, Psotka M. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial. European Heart Journal 2024, 45: ehae666.1068. DOI: 10.1093/eurheartj/ehae666.1068.Peer-Reviewed Original ResearchKCCQ-CSSTertile 1Diuretic doseHeart failureAll-cause mortalityTertile 3Tertile 2Diuretic strategyKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreDoses of loop diureticsHigh doses of furosemideComposite all-cause mortalityBaseline to monthDose of furosemideClinical summary scoreRisk of adverse eventsInteraction p valuePost hoc analysisFurosemide equivalentsLoop diureticsOpen-labelMedian ageNo significant differenceClinical outcomesStudy endpointTorsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure
Krim S, Anand S, Greene S, Chen A, Wojdyla D, Vilaro J, Haught H, Herre J, Eisenstein E, Anstrom K, Pitt B, Velazquez E, Mentz R. Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure. JAMA Cardiology 2024, 9: 182-188. PMID: 37955908, PMCID: PMC10644243, DOI: 10.1001/jamacardio.2023.4776.Peer-Reviewed Original ResearchDe novo heart failureNovo heart failureChronic heart failureHeart failurePatient-reported outcomesCause mortalityHF typeKansas City Cardiomyopathy Questionnaire clinical summary scoreHigher glomerular filtration rateSignificant differencesHeart Failure TrialGlomerular filtration rateClinical summary scoreDiuretic strategyFirst rehospitalizationCause hospitalizationNew onsetTotal hospitalizationsClinical characteristicsClinical profileEjection fractionLoop diureticsFailure TrialHospitalization outcomesNatriuretic peptide
2015
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial
Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology 2015, 11: 585-595. PMID: 26403536, PMCID: PMC5558519, DOI: 10.2217/fca.15.56.Peer-Reviewed Original ResearchConceptsPROTECT trialComparative effectivenessHigher blood urea nitrogenEffects of torsemideProspective randomized trialsHeart failure patientsBlood urea nitrogenGreater disease severityDays postdischargeFailure patientsHeart failureLoop diureticsRandomized trialsRenal hospitalizationUrea nitrogenDisease severityPatientsFurosemideInverse probabilityTorsemideTrialsDeathOutcomesHospitalizationDiureticsTorsemide Versus Furosemide in Heart Failure Patients
Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, O'Connor C, Velazquez EJ. Torsemide Versus Furosemide in Heart Failure Patients. Journal Of Cardiovascular Pharmacology 2015, 65: 438-443. PMID: 25945862, PMCID: PMC4423558, DOI: 10.1097/fjc.0000000000000212.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedComorbidityDatabases, FactualFemaleFurosemideHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedNorth CarolinaRetrospective StudiesRisk FactorsSex FactorsSodium Potassium Chloride Symporter InhibitorsSulfonamidesTertiary Care CentersTorsemideTreatment OutcomeUltrasonographyConceptsHeart failure patientsFailure patientsEffects of torsemideFurosemide-treated patientsMore comorbiditiesCause mortalityBaseline characteristicsProspective trialHeart failureLoop diureticsResidual confoundingPatientsDuke HospitalFurosemideRisk adjustmentTorsemideMortalityLab databaseComorbiditiesDiureticsHospitalTrialsA reappraisal of loop diuretic choice in heart failure patients
Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM. A reappraisal of loop diuretic choice in heart failure patients. American Heart Journal 2015, 169: 323-333. PMID: 25728721, PMCID: PMC4346710, DOI: 10.1016/j.ahj.2014.12.009.Peer-Reviewed Original ResearchConceptsHeart failure patientsHeart failureFailure patientsLoop diureticsNew York Heart Association functional classPlasma brain natriuretic peptide levelsYork Heart Association functional classBrain natriuretic peptide levelsHeart failure severityNatriuretic peptide levelsTranscardiac extractionAldosterone secretionAldosterone systemDiuretic useVentricular functionFurosemide useSymptom managementPharmacologic differencesCardiac fibrosisSurrogate markerMEDLINE searchPeptide levelsControl trialEconomic burdenFurosemide
2011
Diuretic Strategies in Patients with Acute Decompensated Heart Failure
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart B, Mascette AM, Braunwald E, O'Connor CM. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal Of Medicine 2011, 364: 797-805. PMID: 21366472, PMCID: PMC3412356, DOI: 10.1056/nejmoa1005419.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedArea Under CurveCreatinineDiureticsDouble-Blind MethodDrug Administration ScheduleDyspneaFemaleFurosemideHeart FailureHumansInfusions, IntravenousInjections, IntravenousIntention to Treat AnalysisKaplan-Meier EstimateMaleMiddle AgedSodium Potassium Chloride Symporter InhibitorsConceptsAcute decompensated heart failureDecompensated heart failurePatient global assessmentHeart failureCreatinine levelsContinuous infusionHigh-dose strategyGlobal assessmentRenal functionMean changeLow doseHigh doseSignificant differencesCoprimary end pointsSerum creatinine levelsHigh-dose groupLow-dose strategyVisual analog scaleComparison of BolusDiuretic strategyDiuretic therapyTransient worseningGreater diuresisDose adjustmentLoop diuretics